Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBS
Designed to ensure the safety of clinical trial participants and an ethical approach to study design, Institutional Review Boards or IRBs play a critical role in reviewing research protocols and relevant materials. The primary challenge in designing and conducting an IRB trial is that multiple site-specific IRBs will conduct the same review-related tasks but in timeframes that may differ, as site operations and resources vary. This duplication in efforts can create unnecessary redundancy among site-related IRBs, adding time, cost and resources to achieve trial goals.
In September 2022, the U.S. Food and Drug Administration released a proposed rule, IRBs: Cooperative Research, to harmonize with the Department of Health and Human Services’ Common Rule, an existing federal policy implemented to protect participants. In the IRBs: Cooperative Research proposed rule that is currently under review, it would require the use of a single IRB for multi-site clinical trials within the U.S. to ideally help reduce the administrative burden for study teams and IRBs and allow for faster trial start-up while upholding safety standards for participants. This would parallel steps taken recently in Europe, where the EU Clinical Trial Regulation (implemented in 2022) requires a single decision on the ethical acceptability of a clinical trial application within each EU Member State.
Aiming to optimize efficiency in drug development while protecting patient safety, the proposed FDA rule may be beneficial to all key trial stakeholders, including sponsors, site teams and ultimately, patients. Let’s take a closer look at what the real-world impact could be for those involved.
Maintaining trial continuity through COVID-19, it became more apparent than ever how much site teams need support to allow staff to focus on quality patient care, while integrating trial components and technologies that help enhance patient engagement and more.
With the FDA’s current regulations encouraging the use of one IRB among multiple U.S.-based sites for joint review to avoid duplication, it is one way to help reduce site burden. This is especially true for independent investigator sites that do not have their own IRB, as they can make use of a commercial IRB, a “central IRB”, for approval of trials they conduct at their institution. Large academic institutions and hospitals typically have their own IRB (a “local IRB”) and must use their IRB for protocol review and approval at their institution. Under the new single IRB review process, both the independent Investigator sites as well as the academic institutions and hospitals would be obligated to accept the review/approval from an IRB that may not be their “usual” IRB. This may mean institutions with their own IRBs would have to accept review/approval from another institution that is designated as the sole IRB for the study.
While reducing duplicated efforts for sites and IRBs, there will be specific changes to business- as-usual processes that sponsors and sites must account for, including:
Sponsors, their CRO partners and study teams need to consider how to best address these sites and IRBs’ concerns as early as possible in the trial design phase.
In anticipating concerns and challenges to a single IRB strategy early in trial design, there are opportunities to maximize efficiency in steps for protocol review. As trials then rely on a single IRB’s review process, timelines can be accelerated and allow for sponsors and sites to begin participant enrollment activities sooner.
Though the FDA has not stated when the proposed rule may take effect, industry stakeholders should keep a close eye on what is to potentially come down the pike and how to best prepare and plan for shifting to the single IRB design. Currently, we do know the FDA is reviewing comments provided by stakeholders to determine how best to move forward with the rule. So far, there are three noted exceptions to the rule in requiring single IRB review:
As all stakeholders, including the FDA, are focused on keeping patient safety top of mind, while working to ensure much-needed treatments reach them as soon as possible, close monitoring the agency’s steps and updated guidance to help sponsors and sites optimize planning of trials involving IRB review will be a critical piece of the larger drug development puzzle.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
